drugset / Trial / NCT00819104

A Study to Compare the Efficacy, Safety and Tolerability of Selomax With Its Individual Components

NCT00819104

Phase 4 Completed 402 enrolled AstraZeneca St. John's Research Institute · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

This is a randomised, open-label; parallel group, multicentric study comparing the efficacy and safety of fixed-dose-combinations of Metoprolol XL plus Amlodipine with individual components of the combination. SelomaxTM50/5 will also be compared with SelomaxTM 25/2.5 in lowering of BP (SBP and DBP) in Indian patients with essential hypertension.Male and female patients of essential hypertension aged between 18-80 years will be studied. The patients should not have a history of prior cardiovascular disease.

Timeline

Start
2008-11
Primary completion
Completion
2009-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Amlodipine Other / unclassified 2.5 mg Oral
Subject Amlodipine Other / unclassified 5 mg Oral
Subject Metoprolol Other / unclassified 2.5 mg Oral
Subject Metoprolol Other / unclassified 25 mg Oral
Subject Metoprolol Other / unclassified 50 mg Oral